The ongoing REDUCE trial is a 4-yr, phase 3, placebo-controlled study to determine if daily dutasteride 0.5
Eligible men were aged 50–75 yr, with serum prostate-specific antigen ≥2.5
Data were available for 8224 men. Statistically significant but relatively weak correlations were found between average and maximum chronic inflammation and IPSS variables (correlation coefficients, 0.057 and 0.036, respectively; p < 0.001 for total IPSS). Both age and average chronic inflammation were significant in the linear regression after adjustment for other covariates; for both variables, more severe inflammation was associated with higher IPSS scores.
In the REDUCE population, there is evidence of a relationship between the degree of LUTS and the degree of chronic inflammation. Study entry criteria that selected older men and decreased enrolment of men with a greater degree of inflammation and LUTS may have limited the strength of this relationship. The impact of baseline prostate inflammation on progression of LUTS and/or associated complications will be determined during 4-yr longitudinal follow-up.
Keywords: Prostatitis, Inflammation, Benign prostatic hyperplasia, Lower urinary tract symptoms.
a Department of Urology, Queen's University, Kingston General Hospital, Kingston, ON, Canada
b Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
c Department of Surgery, Harvard Medical School, Division of Urology, Brigham and Women's Hospital, Boston, MA, USA
d Bostwick Laboratories, Glen Allen, VA, USA
e GlaxoSmithKline, Biostatistics, Research Triangle Park, NC, USA
f GlaxoSmithKline, Urology Clinical Development and Medical Affairs, Research Triangle Park, NC, USA
Presented at the 22nd Annual EAU Congress, Berlin, Germany, March, 2007.
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.
© 2007 Published by Elsevier B.V.